dc.contributor.author
Nelson, Bryce J. B.
dc.contributor.author
Andersson, Jan D.
dc.contributor.author
Wuest, Frank
dc.contributor.author
Spreckelmeyer, Sarah
dc.date.accessioned
2023-12-07T13:38:30Z
dc.date.available
2023-12-07T13:38:30Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/41829
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-41549
dc.description.abstract
Background: The radiometal gallium-68 (Ga-68) is increasingly used in diagnostic positron emission tomography (PET), with Ga-68-labeled radiopharmaceuticals developed as potential higher-resolution imaging alternatives to traditional Tc-99m agents. In precision medicine, PET applications of Ga-68 are widespread, with Ga-68 radiolabeled to a variety of radiotracers that evaluate perfusion and organ function, and target specific biomarkers found on tumor lesions such as prostate-specific membrane antigen, somatostatin, fibroblast activation protein, bombesin, and melanocortin.
Main body: These Ga-68 radiopharmaceuticals include agents such as [Ga-68]Ga-macroaggregated albumin for myocardial perfusion evaluation, [Ga-68]Ga-PLED for assessing renal function, [Ga-68]Ga-t-butyl-HBED for assessing liver function, and [Ga-68]Ga-PSMA for tumor imaging. The short half-life, favourable nuclear decay properties, ease of radiolabeling, and convenient availability through germanium-68 (Ge-68) generators and cyclotron production routes strongly positions Ga-68 for continued growth in clinical deployment. This progress motivates the development of a set of common guidelines and standards for the Ga-68 radiopharmaceutical community, and recommendations for centers interested in establishing Ga-68 radiopharmaceutical production.
Conclusion: This review outlines important aspects of Ga-68 radiopharmacy, including Ga-68 production routes using a Ge-68/Ga-68 generator or medical cyclotron, standardized Ga-68 radiolabeling methods, quality control procedures for clinical Ga-68 radiopharmaceuticals, and suggested best practices for centers with established or upcoming Ga-68 radiopharmaceutical production. Finally, an outlook on Ga-68 radiopharmaceuticals is presented to highlight potential challenges and opportunities facing the community.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Ga-68-radiolabeling
en
dc.subject
Radiolabeling
en
dc.subject
Ga-68-tracer
en
dc.subject
Radiopharmaceuticals
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Good practices for 68Ga radiopharmaceutical production
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
27
dcterms.bibliographicCitation.doi
10.1186/s41181-022-00180-1
dcterms.bibliographicCitation.journaltitle
EJNMMI Radiopharmacy and Chemistry
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
7
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36271969
dcterms.isPartOf.eissn
2365-421X